- ABOUT US
- CLINICAL PIPELINE
- CONTACT US
- ABOUT US
- CLINICAL PIPELINE
- CONTACT US
- JOIN OUR MAILING LIST
Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)Mar. 3, 2017
The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time. A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170303/reg.jsp
NESS ZIONA, Israel – March 2, 2017 – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.
The meeting will feature a presentation by key opinion leaders H. Joachim Deeg, MD (Fred Hutchinson Cancer Research Center) and David M. Gelmont, MD (formerly at Shire/Baxalta), who will discuss the current treatment landscape for GvHD in bone marrow transplant patients and the unmet medical need for patients who develop acute GvHD. Both KOLs will be available to answer questions following the lunch.
Kamada management will provide an overview of the Company’s ongoing clinical development work with their liquid form of Alpha-1 Antitrypsin (AAT) to treat acute Graft versus Host Disease, including published data to-date, and the company's clinical strategy moving forward.
Dr. Joachim Deeg is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and a Professor in the Division of Medical Oncology at University of Washington School of Medicine. Dr. Deeg treats patients with bone marrow failure such as aplastic anemia and bone cancers, such as myelodysplastic syndrome, leukemia, and myelofibrosis. His clinical expertise is in treating hematologic malignancies, hematopoietic stem cell transplantation, graft-versus-host-disease, and iron overload. Dr. Deeg is also actively involved in research studying inflammatory responses and GvHD, separation of GvHD and GVL effects by AAT, and the pathophysiology of MDS. He has published extensively on the use of hematopoietic cell transplantation in blood cancer patients.
Dr. David Gelmont has over 16 years’ experience in the pharmaceutical industry, conducting and supervising clinical trials in several areas including: neurology, Alzheimer’s disease, immune deficiency, complement biology, autoimmune diseases, GvHD, coagulopathy, sepsis and emphysema. Most recently he was a Senior Medical Director for Baxalta and Shire, and clinical advisor for Kamada's GvHD program. He has hands-on experience with clinical trials ranging from phase-1 through phase-4 as well as PASS and registry type of trials. Additionally, Dr. Gelmont was in charge of submission of multiple INDs and BLAs and represented sponsors in meetings with regulatory agencies including US FDA, EMA, Paul Ehrlich Institute, the Dutch (CCMO), the French (AFSSAPS) competent authorities, and several other ministries of health. Dr. Gelmont’s academic career spanned over 18 years and included managing ICUs, Step-Down units, fellowship programs; he trained nearly 150 fellows in pulmonary and critical care medicine.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170303/reg.jsp and on the Investors section of the Company’s website at www.kamada.com.
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency for which a MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe. Kamada has also completed its Phase 2 clinical trials in the U.S for the treatment of AAT deficiency with inhaled AAT. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA submissions and authorizations. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Chief Financial Officer
LifeSci Advisors, LLC